Hodgkin’s Lymphoma – Pipeline Insight, 2026

DelveInsight’s “Hodgkin’s Lymphoma – Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies developing several pipeline drugs in the Hodgkin’s Lymphoma pipeline landscape. It covers the Hodgkin’s Lymphoma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Hodgkin’s Lymphoma treatment landscape. Learn more about the evolving Hodgkin’s Lymphoma pipeline today @ https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Hodgkin’s Lymphoma Pipeline Report

• DelveInsight’s Hodgkin’s Lymphoma Pipeline Insight report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin’s Lymphoma treatment.

• The leading Hodgkin’s Lymphoma companies include Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others.

• The companies which have their Hodgkin’s Lymphoma drug candidates in the most advanced stage include Affimed Therapeutics, which is evaluating AFM13 in Phase II clinical trials.

• AFM13 by Affimed Therapeutics is a first-in-class innate cell engager (ICE®) designed to activate the innate immune system against CD30-positive hematologic tumors, currently in Phase II clinical evaluation for Hodgkin’s Lymphoma.

• AUR105 by Aurigene Oncology, a small molecule targeting PRMT5, is in Phase I clinical evaluation for Hodgkin’s Lymphoma, with potential across multiple hematologic malignancies.

• The Hodgkin’s Lymphoma pipeline features therapies spanning multiple mechanisms including checkpoint inhibitors, antibody-drug conjugates, targeted small molecules, and innate immune cell engagers, reflecting diversified R&D approaches.

• Global coverage is provided in the Hodgkin’s Lymphoma Pipeline Insight, 2026 report, encompassing late-stage, mid-stage, early-stage, preclinical, and discovery-stage pipeline products.

Download for updates and the latest revolution in Hodgkin’s Lymphoma care @ Hodgkin’s Lymphoma Market Insight

Hodgkin’s Lymphoma Emerging Drugs Profile

• AFM13: Affimed Therapeutics

AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor, creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. The most advanced ICE® clinical program, AFM13 was evaluated as monotherapy in a Phase IIB trial (REDIRECT) in patients with relapsed/refractory peripheral T cell lymphoma, achieving an ORR of 32.4% with a well-managed safety profile. Currently, AFM13 is in Phase II stage of clinical trial evaluation for the treatment of Hodgkin’s Lymphoma.

• AUR105: Aurigene Oncology

AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications including solid tumors, non-Hodgkin lymphoma, and leukemia. AUR105 is administered through the oral route, offering a convenient dosing option for patients. Currently, the drug is being evaluated in Phase I for the treatment of Hodgkin’s Lymphoma.

For more information on the Hodgkin’s Lymphoma Emerging Drugs Profile, download DelveInsight’s comprehensive Hodgkin’s Lymphoma Pipeline Insight report @ Hodgkin’s Lymphoma Emerging Drugs

The Hodgkin’s Lymphoma Pipeline Report Provides

• Detailed insights about companies developing therapies for Hodgkin’s Lymphoma, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Hodgkin’s Lymphoma treatment.

• Hodgkin’s Lymphoma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Hodgkin’s Lymphoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Hodgkin’s Lymphoma market.

Learn more about Hodgkin’s Lymphoma drug opportunities in our comprehensive pipeline report @ Hodgkin’s Lymphoma Unmet Needs

Hodgkin’s Lymphoma Companies

There are 15+ key companies, such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others, developing therapies for Hodgkin’s Lymphoma, with Affimed Therapeutics having its Hodgkin’s Lymphoma drug candidate AFM13 in the most advanced Phase II stage.

DelveInsight’s Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Hodgkin’s Lymphoma products have been categorized under various Molecule types such as:

• Monoclonal Antibody

• Peptides

• Polymer

• Small Molecule

• Gene Therapy

Discover the latest advancements in Hodgkin’s Lymphoma treatment by visiting our website. Stay informed @ Hodgkin’s Lymphoma Market Drivers and Barriers

Scope of the Hodgkin’s Lymphoma Pipeline Report

• Coverage: Global

• Hodgkin’s Lymphoma Companies: Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics, and others

• Hodgkin’s Lymphoma Therapies: AFM13, AUR105, and other pipeline candidates across Phase III, Phase II, Phase I, preclinical, and discovery stages

• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Hodgkin’s Lymphoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hodgkin’s Lymphoma – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Hodgkin’s Lymphoma Key Companies

13. Hodgkin’s Lymphoma Key Products

14. Hodgkin’s Lymphoma Unmet Needs

15. Hodgkin’s Lymphoma Market Drivers and Barriers

16. Hodgkin’s Lymphoma Future Perspectives and Conclusion

17. Hodgkin’s Lymphoma Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services